CDC Awards $1.6 Million Grant for Controversial Hepatitis B Vaccine Study in Guinea-Bissau
核心洞察
The CDC awarded a non-competitive $1.6 million grant to the University of Southern Denmark to conduct a randomized trial of neonatal hepatitis B (搜索) vaccination involving over 14,000 newborns in Guinea-Bissau.
The study will assess all-cause mortality, severe morbidity, and long-term developmental outcomes of hepatitis B (搜索) birth dose vaccination, entering an active scientific debate over non-specific vaccine effects.
Critics question the ethical rationale and methodology, noting that the Danish researchers' previous work has been challenged for over-interpreting findings and emphasizing secondary results that lose statistical significance after proper analysis.
The Centers for Disease Control and Prevention (搜索) has awarded an unsolicited $1.6 million grant to the University of Southern Denmark to conduct a large-scale randomized clinical trial evaluating neonatal hepatitis B (搜索) vaccination in Guinea-Bissau, according to a Federal Register notice published December 18, 2025. The five-year study will enroll more than 14,000 newborns to assess the effects of hepatitis B virus vaccine administered at birth on all-cause mortality, severe morbidity, and long-term neurodevelopmental outcomes.
Study Design and Objectives
The single-blind, multicenter, phase 4 randomized controlled trial will run from January 5, 2026, through January 4, 2031, in Guinea-Bissau, where the World Health Organization recommends three vaccines at birth: Bacille Calmette-Guérin (BCG), oral polio vaccine (OPV0), and hepatitis B vaccine. The study aims to evaluate potential sex-specific differences in vaccine effects and assess broader health impacts beyond hepatitis B (搜索) prevention.
According to the CDC, the research will address limited evidence regarding non-hepatitis-specific health effects of HBV vaccination, as previous studies have focused primarily on BCG and OPV vaccines. The agency determined that the University of Southern Denmark was uniquely qualified based on its experience leading vaccine trials in West Africa and established partnerships with local hospitals and health authorities in Guinea-Bissau.
Scientific Controversy and Methodological Concerns
The grant enters an ongoing scientific debate over non-specific effects (NSEs) of vaccines, defined as health effects beyond protection against target pathogens. Much of the randomized trial evidence supporting NSEs has originated from studies conducted by the Bandim Health Project, led by Christine Stabell Benn and Peter Aaby, who account for approximately 35% of all clinical research articles on NSEs indexed in Web of Science.
A November 2025 analysis published in Vaccine by Henrik Støvring and colleagues reassessed randomized controlled trials conducted by the Bandim Health Project following Danish media reports raising concerns about research practices. The review found that in 23 of 25 randomized trial papers, Bandim Health researchers emphasized secondary findings, and in 22 cases those findings were no longer statistically significant after appropriate statistical adjustments.
The authors reported multiple methodological concerns, including unpublished primary outcomes, outcome switching, reliance on statistically fragile subgroup analyses, selective emphasis on secondary findings when primary outcomes were null, and underpowered sample-size calculations based on optimistic assumptions. After applying Holm-Bonferroni and Benjamini-Hochberg procedures to address false-positive findings from multiple hypothesis testing, many previously reported statistically significant results did not remain significant.
Expert Criticism and Ethical Concerns
Several experts questioned the ethical and scientific rationale for conducting another hepatitis B vaccine study, citing extensive existing evidence supporting the vaccine's safety and effectiveness. Angela Rasmussen, a virologist at the University of Saskatchewan, said awarding a noncompetitive grant for the research gives the "appearance of blatant cronyism."
Amesh A. Adalja of Johns Hopkins Center for Health Security noted that safety data for hepatitis B (搜索) vaccines are "very robust" and that additional studies may represent a misallocation of limited research funding. "The data that supports the safety advocacy of the current hepatitis B vaccines is very robust," Adalja said. "Continuing to do studies on a question that is already been answered sufficiently is a waste of resources that could better be used answering new questions."
Researchers also raised ethical concerns about the study design. Rasmussen noted that it would not be ethical to provide a birth dose of hepatitis B vaccine to some babies but not others, given that doctors know the immunization saves lives. Exposing thousands of babies to "a significant risk" of hepatitis B (搜索) "in a low-income country with limited health care resources" would be "wildly unethical and a disgraceful use of American taxpayer money," she said.
Policy Context and Implications
The study comes after the Advisory Committee on Immunization Practices voted earlier this month to abandon a 34-year-old recommendation to vaccinate all newborns for hepatitis B (搜索), a practice that has reduced infections in children and adolescents by 99%. Since 1991, the universal HBV birth dose has prevented an estimated 90,100 childhood deaths, with safety demonstrated in hundreds of studies over four decades.
The acting CDC director followed ACIP advice, recommending a birth dose of hepatitis B vaccine only for babies whose mothers are infected with the virus or whose infection status is unknown. Jake Scott of Stanford University School of Medicine warned that this change will lead more babies to develop hepatitis B (搜索), which can cause liver cancer (搜索), liver failure (搜索) and death.
Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, noted that Guinea-Bissau's findings are unlikely to be relevant to US vaccine policy, given the nation "has very different population demographics from the US and has a health system which is very different from the US."
Research Timeline and Expected Outcomes
According to the CDC, findings from the study are expected to inform global immunization policy and practice, particularly regarding the broader health effects of neonatal hepatitis B (搜索) vaccination beyond prevention of hepatitis B virus infection. An HHS spokesman said the study will fill a vital need, stating that "this award supports an independent study designed to answer important questions about the broader health effects of the hepatitis B birth dose."
As the trial proceeds, its results are expected to contribute additional randomized evidence to ongoing discussions about neonatal hepatitis B (搜索) vaccination. How these findings are interpreted alongside the existing body of vaccine safety and effectiveness data may have implications for global immunization policy, though critics argue the research represents validation-seeking rather than evidence-gathering.